Skip to main
  1. Stocks
  2. Envoy Medical Inc
  3. Forecast
COCH

COCH Stock Forecast & Price Target

COCH Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Envoy Medical is attractive because its fully implanted Acclaim cochlear implant addresses a large unmet need by eliminating the external component that can limit daily use and adoption, while leveraging the ear’s natural anatomy to differentiate it from traditional cochlear implants. Clinical execution has been encouraging: the pivotal trial has surpassed the 6-month follow-up milestone in 56 patients, the first 10 Stage 1 participants showed mean CNC word recognition improving to 53.2% from 39.2% at six months and 15.2% pre-implantation, and no protocol-defined serious adverse events were reported. Although revenue was only $66K in 3Q26 and net loss was $5.2M, the two PMA modules already submitted and the path toward a 2Q27 filing support a credible regulatory runway.

Bears say

Envoy Medical is facing a weak liquidity profile, with cash declining from $19.7M at the end of June 2026 to $14.6M at the end of September 2026 while operating cash outflows remained heavy at ($5.5M) in 2Q26 and ($5.0M) in 3Q26. The company’s dependence on potential warrant exercises is a risk because the outstanding Series A-1 and Series A-2 warrants may need to generate up to $48M of gross proceeds to support operations, yet management believes additional capital may still be needed within the next 12 months absent those exercises. Near-term financial pressure is compounded by the requirement to regain NASDAQ minimum bid-price compliance by November 16, 2026, underscoring a balance-sheet and financing overhang that weakens the outlook.

COCH has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Envoy Medical Inc and is not a guaranteed prediction by Public.com or investment advice.

COCH Analyst Forecast & Price Prediction

Get the latest COCH stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in COCH

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Envoy Medical Inc (COCH) Forecast

Analysts have given COCH a Strong Buy based on their latest research and market trends.

According to 3 analysts, COCH has a Strong Buy consensus rating as of Nov 13, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $15, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $15, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Envoy Medical Inc (COCH)


COCH Analyst Forecast & Price Prediction

Get the latest COCH stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in COCH

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover COCH stock data and trends